Avidity Biosciences Inc

RNA

72.900USD

+0.080+0.11%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Avidity Biosciences Inc's Score

Industry at a Glance

Industry Ranking

56 / 159

Overall Ranking

166 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Avidity Biosciences Inc Highlights

StrengthsRisks

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 18.14% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.90M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 10.90M.

Undervalued

The company’s latest PE is -17.38, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 151.27M shares, decreasing 5.87% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 8.53K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.87.

Analyst Rating

Based on 14 analysts

Hold

Current Rating

72.615

Target Price

-0.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Avidity Biosciences Inc is 7.29, ranking 120 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 12.47M, representing a year-over-year increase of 434.03%, while its net profit experienced a year-over-year increase of 116.97%.

Score

Industry at a Glance

Previous score

7.29

Change

0



Financials

7.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.96

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.10

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.49

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Avidity Biosciences Inc is 6.74, ranking 115 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -17.38, which is -90.64% below the recent high of -1.63 and -13.12% above the recent low of -19.66.

Score

Industry at a Glance

Previous score

6.74

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 56/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Avidity Biosciences Inc is 6.43, ranking 129 out of 159 in the Pharmaceuticals industry. The average price target is 72.00, with a high of 96.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

6.43

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Avidity Biosciences Inc is 8.27, ranking 52 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 73.23 and the support level at 72.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.95

Change

1.32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Avidity Biosciences Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 97.78%, representing a quarter-over-quarter decrease of 2.10%. The largest institutional shareholder is The Vanguard, holding a total of 13.62M shares, representing 8.80% of shares outstanding, with 15.05% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

20.11M

+27.11%

The Vanguard Group, Inc.

Star Investors

13.19M

+42.98%

Wellington Management Company, LLP

10.07M

+8.82%

T. Rowe Price Associates, Inc.

Star Investors

9.65M

-9.54%

RA Capital Management, LP

8.64M

+18.92%

Janus Henderson Investors

14.52M

+19.71%

BlackRock Institutional Trust Company, N.A.

7.91M

-3.29%

Avoro Capital Advisors LLC

7.64M

+8.44%

Bristol Myers Squibb

5.08M

--

State Street Investment Management (US)

4.89M

+16.35%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Avidity Biosciences Inc is 4.87, ranking 81 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Avidity Biosciences Inc

RNA

7.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment